Phathom Pharmaceuticals (Nasdaq: PHAT) will host a live webcast on Thursday, July 30, 2026, at 8:00 am EDT to report its second quarter 2026 financial results and provide a business update.
The event will be accessible via the company’s website, with a recording available for 90 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PHAT
-2.65%
-2.65%News Effect
On the day this news was published, PHAT declined 2.65%, reflecting a moderate negative market reaction.
The effective S-3ASR expires January 7, 2029 and permits offerings with terms specified in prospectu...
Analysis
The effective S-3ASR expires January 7, 2029 and permits offerings with terms specified in prospectus supplements. This announcement schedules results; moderate short positioning adds volatility risk, while no recent insider activity was reported.
Key Figures
Reporting period:Second quarter 2026Webcast date:July 30, 2026Webcast time:8:00 am EDT+1 more
Scheduled fourth-quarter and full-year 2025 results for February 26 webcast
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Both tag-matched prior earnings-date announcements were followed by positive 24-hour reactions, although this article provided scheduling information rather than financial results.
Key Terms
potassium-competitive acid blocker, pcab, non-erosive gerd, h. pylori infection
4 terms
potassium-competitive acid blockermedical
"vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB)"
A potassium-competitive acid blocker is a type of medication that reduces stomach acid by blocking the cellular “pump” that produces acid, using a chemical that competes with potassium to stop the pump from working. For investors, it matters because this drug class can offer faster, longer-lasting acid control than older therapies, affecting market demand, pricing power, regulatory scrutiny, and commercial potential in conditions like ulcers and reflux.
pcabmedical
"potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada"
PCAB is the Philippine Contractors Accreditation Board, the government body that issues licenses and size classifications to construction contractors—think of it like a combined business license and capacity rating for builders. Investors pay attention because a contractor’s PCAB license and grade determine which public and private projects it can legally bid on and the maximum project size it may undertake; changes in status can directly affect a firm’s revenue opportunities and regulatory risk profile.
non-erosive gerdmedical
"relief of heartburn associated with Non-Erosive GERD in adults"
Non-erosive GERD is a form of acid reflux where people experience typical symptoms such as heartburn and regurgitation but endoscopic exams show no visible injury to the lining of the esophagus. Think of it like a smoke alarm going off without any visible fire — the problem causes discomfort but isn’t showing obvious tissue damage. It matters to investors because this subtype often responds differently to treatments, affects trial design and patient selection, and represents a large patient group that shapes market size, pricing and reimbursement for therapies.
h. pylori infectionmedical
"for the treatment of H. pylori infection in adults"
H. pylori infection is an infection of the stomach lining caused by the bacterium Helicobacter pylori that can cause chronic stomach inflammation, ulcers, and raise the long‑term risk of stomach cancer. For investors it matters because diagnosis, treatment, and prevention drive demand for drugs, diagnostics and medical procedures, influence clinical trial outcomes and regulatory decisions, and can affect sales and valuation in healthcare and consumer health businesses — similar to how a persistent pest can change maintenance and replacement needs for a property.
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT
FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, July 30, 2026, to report its second quarter 2026 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.
About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
When will Phathom Pharmaceuticals (PHAT) report its Q2 2026 financial results?
Phathom Pharmaceuticals will report its Q2 2026 financial results on Thursday, July 30, 2026, at 8:00 am EDT. According to Phathom, management will host a live webcast that also includes a broader business update for investors and stakeholders.
How can investors access the Phathom Pharmaceuticals (PHAT) Q2 2026 earnings webcast?
Investors can access the Q2 2026 webcast through the Events & Presentations section of Phathom’s investor website. According to Phathom, the live webcast link and additional presentation details will be available at investors.phathompharma.com/news-events/events-and-presentations.
Will a replay be available for the Phathom Pharmaceuticals (PHAT) Q2 2026 earnings call?
Yes, a replay of the Q2 2026 earnings call will be available for 90 days after the event. According to Phathom, the recording can be accessed following the conclusion of the webcast via the company’s Events & Presentations webpage.
What topics will Phathom Pharmaceuticals cover during the Q2 2026 webcast for PHAT shareholders?
The webcast will cover second quarter 2026 financial results and a company business update. According to Phathom, management will discuss financial performance and provide updates related to its gastrointestinal disease treatment portfolio, including commercialization and development activities.
Where is Phathom Pharmaceuticals (PHAT) headquartered and what is its business focus?
Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey and focuses on gastrointestinal disease treatments. According to Phathom, it develops and commercializes vonoprazan-based products, including VOQUEZNA tablets and VOQUEZNA treatment packs for conditions such as GERD and H. pylori infection.
What products does Phathom Pharmaceuticals (PHAT) currently market in the United States?
Phathom currently markets VOQUEZNA (vonoprazan) tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK in the U.S. According to Phathom, these products are used for Non-Erosive GERD, Erosive GERD, associated heartburn relief, and H. pylori infection in adults.
